Tag: KDC-MN-360

  • Stamulumab (MYO-029)

    Anti-myostatin monoclonal antibody (research)

    A humanized monoclonal antibody selective for myostatin (GDF-8); the first-in-class anti-myostatin antibody investigated for muscular dystrophy.

    Abstract

    Stamulumab (MYO-029; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody selective for myostatin (GDF-8), developed at Wyeth (now Pfizer). The compound binds circulating myostatin in plasma, neutralizing the negative regulator of muscle growth. Phase 1/2 trials in adults with becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy demonstrated tolerability but limited muscle mass increases (approximately 0.5 to 1 percent), which were considered insufficient to justify advancement. The compound is the first-in-class anti-myostatin antibody and informed subsequent development of bimagrumab (broader receptor target), domagrozumab, and landogrozumab. Used as a research compound for selective myostatin neutralization.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.